Shares of Bone Biologics Co. (OTC:BBLG – Get Free Report) fell 6.9% during trading on Monday . The stock traded as low as $0.98 and last traded at $0.99. 1,045,269 shares changed hands during mid-day trading, an increase of 364% from the average session volume of 225,061 shares. The stock had previously closed at $1.06.
Bone Biologics Price Performance
The company has a fifty day moving average of $1.09 and a 200 day moving average of $1.43. The stock has a market cap of $2.46 million, a P/E ratio of -0.02 and a beta of 0.49.
About Bone Biologics
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Further Reading
- Five stocks we like better than Bone Biologics
- How to invest in marijuana stocks in 7 steps
- Sizing Up a New Opportunity for NVIDIA Investors
- Retail Stocks Investing, Explained
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Short Selling – The Pros and Cons
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
